adjuvant Archives -

Radiology technician examens mammography test

News/ News/ News/ Oncology/ Sales and Marketing

AZ, Merck get EU nod for Lynparza as adjuvant breast cancer therapy

Phil Taylor adjuvant, AstraZeneca, breast cancer, EU, Lynparza, Merck & Co, Oncology, targeted oncology 0 Comment

The European Commission has cleared AstraZeneca and Merck & Co’s Lynparza as an adjuvant treatment for breast cancer,

AZ, Merck get EU nod for Lynparza as adjuvant breast cancer therapy

https://pharmaphorum.com/news/az-merck-get-eu-nod-for-lynparza-as-adjuvant-breast-cancer-therapy/

News/ News/ News/ Oncology/ R&D

BMS’ plan to move Opdivo into adjuvant RCC gets knocked back

Phil Taylor adjuvant, Bristol-Myers Squibb, immuno-oncology, Oncology, Opdivo, renal cell carcinoma 0 Comment

Bristol-Myers Squibb has revealed that its checkpoint inhibitor combination of Opdivo and Yervoy failed a phase 3 trial

BMS’ plan to move Opdivo into adjuvant RCC gets knocked back

https://pharmaphorum.com/news/bms-plan-to-move-opdivo-into-adjuvant-rcc-gets-knocked-back/

News/ News/ Oncology

Roche’s Tecentriq extends lead over Keytruda in adjuvant NSCLC

Phil Taylor adjuvant, immuno-oncology, Keytruda, Merck & Co, Non-small cell lung cancer, Oncology, regulatory approval, Roche, Tecentriq 0 Comment

While Merck & Co’s Keytruda is the undisputed leader of the non-small cell lung cancer (NSCLC) category, there’s

Roche’s Tecentriq extends lead over Keytruda in adjuvant NSCLC

https://pharmaphorum.com/news/roches-tecentriq-extends-lead-over-keytruda-in-adjuvant-nsclc/

News/ News/ Oncology

Merck fights back against Roche in adjuvant lung cancer therapy

Phil Taylor adjuvant, Keytruda, Merck & Co, Non-small cell lung cancer, Roche, Tecentriq 0 Comment

Merck & Co’s Keytruda is poised to move even earlier in the treatment of patients with non-small cell

Merck fights back against Roche in adjuvant lung cancer therapy

https://pharmaphorum.com/news/merck-fights-back-against-roche-in-adjuvant-lung-cancer-therapy/

News/ News/ Sales and Marketing

GSK gets £1.4bn sales lift from COVID-19 products in 2021

Phil Taylor adjuvant, COVID-19, Financial, GlaxoSmithKline, xevudy 0 Comment

GlaxoSmithKline’s COVID-19 products – antibody drug Xevudy and a vaccine adjuvant – helped drive a 5% increase in

GSK gets £1.4bn sales lift from COVID-19 products in 2021

https://pharmaphorum.com/news/gsk-gets-1-4bn-sales-lift-from-covid-19-products-in-2021/

News/ News/ Oncology

Merck gets EU nod for Keytruda in adjuvant kidney cancer

Phil Taylor adjuvant, EU, immuno-oncology, Keytruda, Merck & Co, Oncology, regulatory approval, renal cell carcinoma 0 Comment

Merck & Co has passed another milestone in its drive to move PD-1 inhibitor Keytruda earlier in the

Merck gets EU nod for Keytruda in adjuvant kidney cancer

https://pharmaphorum.com/news/merck-gets-eu-nod-for-keytruda-in-adjuvant-kidney-cancer/

News/ News/ Oncology

Chasing Roche, Merck unveils adjuvant lung cancer data for Keytruda

Phil Taylor adjuvant, Keytruda, Merck & Co, Non-small cell lung cancer, Roche, Tecentriq 0 Comment

Merck & Co’s Keytruda is the undisputed market leader in immunotherapy for non-small cell lung cancer (NSCLC), but

Chasing Roche, Merck unveils adjuvant lung cancer data for Keytruda

https://pharmaphorum.com/news/chasing-roche-merck-unveils-adjuvant-lung-cancer-data-for-keytruda/

Market Access/ News/ News

NICE gives Keytruda parity with Opdivo for adjuvant melanoma

Phil Taylor adjuvant, HEOR, melanoma, Merck & Co, NHS, NICE 0 Comment

After three years of availability via the Cancer Drugs Fund (CDF), MSD’s checkpoint inhibitor Keytruda has now been

NICE gives Keytruda parity with Opdivo for adjuvant melanoma

https://pharmaphorum.com/news/after-stint-on-cdf-nice-makes-keytruda-routine-for-adjuvant-melanoma/

News/ News/ Oncology

Merck claims another adjuvant okay from FDA for Keytruda

Phil Taylor adjuvant, fda, Keytruda, melanoma, Merck & Co, regulatory approval 0 Comment

Merck & Co’s strategy of pushing Keytruda earlier in the treatment pathway for cancers has secured anther victory,

Merck claims another adjuvant okay from FDA for Keytruda

https://pharmaphorum.com/news/merck-claims-another-adjuvant-okay-from-fda-for-keytruda/

Trending

adjuvant

Login